Fig. 3: Efficacy of F365 and polymyxin B in a neutropenic mouse pneumonia model against polymyxin-susceptible (a–c) and polymyxin-resistant (PM-R) (d–e) MDR clinical isolates.
From: A synthetic lipopeptide targeting top-priority multidrug-resistant Gram-negative pathogens
a P. aeruginosa FADDI-PA038 (F365 MIC = 0.5 μg/mL, polymyxin B MIC = 0.5 μg/mL; n = 4). b A. baumannii FADDI-AB051 (carbapenem-resistant, F365 and polymyxin B MIC = 0.5 μg/mL; n = 4). c K. pneumoniae FADDI-KP065 (carbapenem-resistant, F365 MIC <0.125 μg/mL, polymyxin B MIC = 0.25 μg/mL; n = 4). d P. aeruginosa FADDI-PA102 (carbapenem-resistant, F365 and polymyxin B MIC = 4 μg/mL; n = 3). e A. baumannii FADDI-AB156 (carbapenem-resistant, F365 MIC = 4 μg/mL, polymyxin B MIC = 8 μg/mL; n = 3). f K. pneumoniae FADDI-KP132 (mcr-1 positive, F365 and polymyxin B MIC = 8 μg/mL; n = 4). F365, polymyxin B or the vehicle was administered (in three divided doses) intraperitoneally (a–c) or subcutaneously (d–f) every 8 h over 24 h. Data are shown as mean ± s.e.m. Two-tailed one-way ANOVA with Tukey HSD post-hoc test (FDR adjustment for multiple comparisons) was used to compare different groups. Statistical details are provided as a Source Data file. FDR-adjusted P-values *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 relative to the pre-treatment group. EUCAST breakpoints of colistin were employed: Susceptible ≤ 2 μg/mL, Resistant > 2 μg/mL.
